🇺🇸 FDA
Patent

US 9499868

Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

granted A61KA61K38/02A61K38/16

Quick answer

US patent 9499868 (Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/02, A61K38/16, A61K45/06, A61P